Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure: The RELAX HF Study
Lead Physician: Debra Meyers, M.D.
This is a double-blind, placebo controlled study testing the hypothesis that chronic PDE-5 inhibition improves exercise capacity and clinical status in patients with diastolic heart failure. The study also measures the effect of this therapy on key pathophysiological parameters which are believed to impact clinical status and exercise performance in diastolic heart failure.